David E. Coutant

672 total citations
33 papers, 491 citations indexed

About

David E. Coutant is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, David E. Coutant has authored 33 papers receiving a total of 491 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Endocrinology, Diabetes and Metabolism, 14 papers in Surgery and 4 papers in Molecular Biology. Recurrent topics in David E. Coutant's work include Diabetes Management and Research (19 papers), Diabetes Treatment and Management (16 papers) and Pancreatic function and diabetes (14 papers). David E. Coutant is often cited by papers focused on Diabetes Management and Research (19 papers), Diabetes Treatment and Management (16 papers) and Pancreatic function and diabetes (14 papers). David E. Coutant collaborates with scholars based in United States, Germany and Singapore. David E. Coutant's co-authors include Helle Linnebjerg, Stephen D. Hall, Jennifer Leohr, Elizabeth LaBell, Mary Anne Dellva, Mary Seger, Laiyi Chua, Qianyi Zhang, Mark E. Meyerhoff and Danny Soon and has published in prestigious journals such as Diabetes Care, Diabetes and Journal of Chromatography A.

In The Last Decade

David E. Coutant

31 papers receiving 476 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David E. Coutant United States	14	271	183	118	63	55	33	491
Akifumi Kogame Japan	9	129 0.5×	127 0.7×	57 0.5×	186 3.0×	32 0.6×	14	380
I. F. Douek United Kingdom	5	108 0.4×	66 0.4×	55 0.5×	94 1.5×	24 0.4×	8	403
Yangliang Ye China	11	103 0.4×	96 0.5×	17 0.1×	149 2.4×	19 0.3×	23	364
Nancy-Ellen Haynes United States	6	277 1.0×	353 1.9×	71 0.6×	410 6.5×	10 0.2×	7	697
Bolette Husman Sweden	13	266 1.0×	48 0.3×	144 1.2×	178 2.8×	13 0.2×	19	483
Karl H. Clodfelter United States	7	148 0.5×	28 0.2×	105 0.9×	338 5.4×	19 0.3×	8	590
Lars-Göran Bladh Sweden	6	208 0.8×	37 0.2×	117 1.0×	162 2.6×	21 0.4×	6	434
Lida Qi United States	10	183 0.7×	335 1.8×	61 0.5×	403 6.4×	15 0.3×	15	656
Pascal Druzgala United States	11	46 0.2×	58 0.3×	43 0.4×	106 1.7×	13 0.2×	24	456

Countries citing papers authored by David E. Coutant

Since Specialization

Citations

This map shows the geographic impact of David E. Coutant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Coutant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Coutant more than expected).

Fields of papers citing papers by David E. Coutant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David E. Coutant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Coutant. The network helps show where David E. Coutant may publish in the future.

Co-authorship network of co-authors of David E. Coutant

This figure shows the co-authorship network connecting the top 25 collaborators of David E. Coutant. A scholar is included among the top collaborators of David E. Coutant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David E. Coutant. David E. Coutant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Coutant, David E., Jessica Rehmel, Donna M. Edwards, & Stephen D. Hall. (2025). A novel physiologically-based pharmacokinetic model to estimate reduced CYP3A4 activity in cancer patients utilizing the neutrophil-to-lymphocyte ratio as an inflammatory marker. European Journal of Clinical Pharmacology. 81(6). 853–862.

Morse, Bridget L., Shobha Bhattachar, Xiaosu Ma, et al.. (2025). Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants. Clinical Pharmacology in Drug Development. 15(1). e1594–e1594. 1 indexed citations

Datta‐Mannan, Amita, Arie Regev, David E. Coutant, et al.. (2024). Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL‐17A ( LY3509754 ): A Phase I Randomized Placebo‐Controlled Study. Clinical Pharmacology & Therapeutics. 115(5). 1152–1161. 14 indexed citations

Aronson, Ronnie, Torben Biester, Jennifer Leohr, et al.. (2023). Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus. Diabetes Obesity and Metabolism. 25(7). 1964–1972. 3 indexed citations

Leohr, Jennifer, Mary Anne Dellva, Elizabeth LaBell, et al.. (2023). Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion. Diabetes Obesity and Metabolism. 26(1). 215–223. 2 indexed citations

Coutant, David E., David W. Boulton, Upendra P. Dahal, et al.. (2022). Therapeutic Protein Drug Interactions: A White Paper From the International Consortium for Innovation and Quality in Pharmaceutical Development. Clinical Pharmacology & Therapeutics. 113(6). 1185–1198. 11 indexed citations

Leohr, Jennifer, Mary Anne Dellva, Elizabeth LaBell, David E. Coutant, & Helle Linnebjerg. (2022). Evaluation of the Pharmacokinetic Profile of Ultra Rapid Lispro Administered Subcutaneously at Different Injection Sites. Clinical Therapeutics. 44(6). 836–847.

Leohr, Jennifer, Mary Anne Dellva, Elizabeth LaBell, et al.. (2020). Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects. Clinical Therapeutics. 42(9). 1762–1777.e4. 15 indexed citations

Heise, Tim, Helle Linnebjerg, David E. Coutant, et al.. (2020). Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. Diabetes Obesity and Metabolism. 22(10). 1789–1798. 47 indexed citations

10.

Linnebjerg, Helle, Qianyi Zhang, Elizabeth LaBell, et al.. (2020). Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial. Clinical Pharmacokinetics. 59(12). 1589–1599. 45 indexed citations

11.

Linnebjerg, Helle, Elizabeth LaBell, Mary Anne Dellva, David E. Coutant, & Jennifer Leohr. (2020). Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects. Diabetes Therapy. 11(8). 1709–1720. 4 indexed citations

12.

Leohr, Jennifer, Mary Anne Dellva, David E. Coutant, et al.. (2020). Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study. Clinical Pharmacokinetics. 59(12). 1601–1610. 26 indexed citations

13.

Coutant, David E. & Stephen D. Hall. (2018). Disease–Drug Interactions in Inflammatory States via Effects on CYP‐Mediated Drug Clearance. The Journal of Clinical Pharmacology. 58(7). 849–863. 51 indexed citations

14.

Byrd, Richard A., Rebecca A. Owens, Jamie L. Blackbourne, et al.. (2017). Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR®/ABASAGLAR®) approved in the European Union. Regulatory Toxicology and Pharmacology. 88. 56–65. 4 indexed citations

15.

Linnebjerg, Helle, Mary Seger, David E. Coutant, et al.. (2015). Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies. Diabetes Care. 38(12). 2226–2233. 73 indexed citations

16.

Breslin, William J., et al.. (2014). Assessment of fetal exposure risk following seminal excretion of a therapeutic IgG4 (T-IgG4) monoclonal antibody using a rabbit model. Reproductive Toxicology. 48. 124–131. 8 indexed citations

17.

Seger, Mary, et al.. (2014). PO427 COMPARATIVE PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 INSULIN GLARGINE PRODUCTS, LY2963016 AND LANTUS® IN HEALTHY SUBJECTS AT 2 DOSE LEVELS. Diabetes Research and Clinical Practice. 106. S264–S264. 5 indexed citations

18.

Linnebjerg, Helle, et al.. (2014). PO428 COMPARATIVE PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF LY2963016 INSULIN GLARGINE AND EU- AND US-APPROVED VERSIONS OF LANTUS® INSULIN GLARGINE IN HEALTHY SUBJECTS. Diabetes Research and Clinical Practice. 106. S264–S265. 4 indexed citations

19.

Jhee, S. S., Amy S. Chappell, Victoria Zarotsky, et al.. (2006). Multiple‐Dose Plasma Pharmacokinetic and Safety Study of LY450108 and LY451395 (AMPA Receptor Potentiators) and Their Concentration in Cerebrospinal Fluid in Healthy Human Subjects. The Journal of Clinical Pharmacology. 46(4). 424–432. 26 indexed citations

20.

Coutant, David E., et al.. (1998). Selective separation of fullerenes on hydroxyphenyl-triphenylporphyrin–silica stationary phases. Journal of Chromatography A. 824(2). 147–157. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact